{"componentChunkName":"component---node-modules-gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/zh-Hant/reddit/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","result":{"data":{"site":{"siteMetadata":{"title":"å›½å¤–è‚¡å¸‚çƒ­é—¨","description":"ç”¨ä¸­æ–‡æµè§ˆå›½å¤–è‚¡ç¥¨ç¤¾åŒºé‡Œçš„çƒ­é—¨è®¨è®º","social":[{"name":"Reddit Stocks","url":"https://www.reddit.com/r/stocks","external":true,"prefetch":null},{"name":"Reddit Investing","url":"https://www.reddit.com/r/investing","external":true,"prefetch":null},{"name":"Reddit Bogleheads","url":"https://www.reddit.com/r/Bogleheads/","external":true,"prefetch":null},{"name":"Buzzing","url":"https://www.buzzing.cc/","external":true,"prefetch":null}],"menuLinks":[{"name":"æ¯å‘¨ç²¾é€‰","url":"/issues","external":null,"prefetch":null}],"localize":[{"title":"Buzzing on Stocks","description":"See popular discussions in foreign stock communities in your native language","locale":"en","social":[{"name":"Reddit","url":"https://www.reddit.com/","external":true,"prefetch":null}],"menuLinks":[{"name":"Weekly Selection","url":"/en/issues","external":null,"prefetch":null}]},{"title":"åœ‹å¤–è‚¡å¸‚ç†±é–€","description":"ç”¨ä¸­æ–‡ç€è¦½åœ‹å¤–è‚¡ç¥¨ç¤¾å€è£¡çš„ç†±é–€è¨è«–","locale":"zh-Hant","social":null,"menuLinks":[{"name":"æ¯é€±ç²¾é¸","url":"/zh-Hant/issues","external":null,"prefetch":null}]},{"title":"ç±³å›½æ ªå¼å¸‚å ´äººæ°—ã®è©±ã—åˆã„ã¾ã™","description":"äººæ°—ã®ç±³å›½æ ªå¼å¸‚å ´ã®è©±ã—åˆã„ã¾ã‚’æ—¥æœ¬èªã§é–²è¦§","locale":"ja","social":null,"menuLinks":[{"name":"æ¯é€±ç²¾é¸","url":"/ja/issues","external":null,"prefetch":null}]}]}},"blogPost":{"__typename":"SocialMediaPost","id":"RedditPost-kv332t","excerpt":" * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gains 20%Â in premarket on promising results\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-ofâ€¦","body":"<!-- SC_OFF --><div class=\"md\"><ul>\n<li>Eli Lilly (NYSE:<a href=\"https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">LLY</a>) gains 20%Â in premarket on <a href=\"https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of-alzheimers-disease-in-positive-phase-2-trial?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">promising results</a> from <a href=\"https://clinicaltrials.gov/ct2/show/NCT03367403?cond=trailblazer&amp;draw=2&amp;rank=1&amp;source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">Phase 2 TRAILBLAZER-ALZ study</a>, evaluating donanemab, an antibody that targets a  modified form of beta amyloid called N3pG, for Alzheimer&#39;s disease  (AD). The study met the primary endpoint of change from baseline to 76  weeks in AD rating scale.</li>\n<li>Data  showed that donanemab slowed the decline in a composite measure of  cognition and daily function by 32%, compared to placebo.</li>\n<li>Safety profile was consistent with observations from Phase 1 data.</li>\n<li>Full  results of the TRAILBLAZER-ALZ study will be presented at a future  medical congress and submitted for publication in a peer-reviewed  clinical journal.</li>\n<li>Lilly plans to  discuss these results with regulators to assess next steps for  donanemab. In addition, TRAILBLAZER-EXT is an ongoing trial for those  who participated in TRAILBLAZER-ALZ.</li>\n<li>Safety, tolerability and efficacy of donanemab are also being evaluated in another <a href=\"https://clinicaltrials.gov/ct2/show/NCT04437511?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">Phase 2 study TRAILBLAZER-ALZ 2</a>.</li>\n<li>Progress on Alzheimer&#39;s treatments was one reason cited by BofA in picking Lilly as a <a href=\"https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link\">top name for 2021</a>.</li>\n</ul>\n\n<p><a href=\"https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study\">https://seekingalpha.com/news/3650196-eli-lilly-up-20-after-donanemab-shows-clinical-benefit-in-mid-stage-alzheimers-study</a></p>\n</div><!-- SC_ON -->","slug":"/reddit/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","title":"Eli Lilly up 20% after donanemab shows clinical benefit in mid-stage Alzheimer's study","tags":["investing","reddit"],"date":"January 13, 2021","dateISO":"2021-01-13T00:11:37.000Z","datetime":"2021-01-13 00:11","image":null,"imageAlt":null,"socialImage":null,"fields":{"basePath":"/"},"thirdPartyId":"kv332t","provider":"Reddit","url":"https://www.reddit.com/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","originalUrl":"https://www.reddit.com/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","imageRemote":null,"video":null,"channel":"investing","channelUrl":"https://www.reddit.com/r/investing","author":"Omg_Keynes","authorUrl":"https://www.reddit.com/user/Omg_Keynes","authorImage":null,"authorSlug":"Omg_Keynes","score":35,"views":null,"sharedCount":null,"likeCount":null,"sharedContent":null,"parent":{"__typename":"RedditJson","localize":[{"title":"Eli Lilly legt um 20% zu, nachdem Donanemab klinischen Nutzen in Alzheimer-Studie im mittleren Stadium zeigt","the_new_excerpt":" * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gewinnt 20% im vorbÃ¶rslichen Handel aufgrund vielversprechender Ergebnisse\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of...","locale":"zh"},{"title":"Eli Lilly legt um 20% zu, nachdem Donanemab klinischen Nutzen in Alzheimer-Studie im mittleren Stadium zeigt","the_new_excerpt":" * Eli Lilly (NYSE:LLY\n   [https://seekingalpha.com/symbol/LLY?source=content_type%3Areact%7Cfirst_level_url%3Anews%7Csection%3Amain_content%7Cbutton%3Abody_link])\n   gewinnt 20% im vorbÃ¶rslichen Handel aufgrund vielversprechender Ergebnisse\n   [https://seekingalpha.com/pr/18145426-lillys-donanemab-slows-clinical-decline-of...","locale":"zh-Hant"}]}},"previous":{"id":"RedditPost-l6c5tg","excerpt":"To the SEC retards in this sub: go fuck yourself. Why donâ€™t you start\ninvestigating why companies can shut down trading so their hedge fund buddies\ndonâ€™t lose money. But when people lose money itâ€™s completely ok. Eat a dick.","slug":"/reddit/r/wallstreetbets/comments/l6c5tg/just_read_a_new_york_times_article_saying_the_sec/","title":"Just read a New York Times article saying the SEC is reviewing this sub and what is going on....ğŸ®ğŸ®ğŸ®ğŸ®ğŸ® (SEC PLS READ)","date":"January 27, 2021","__typename":"SocialMediaPost","parent":{"__typename":"RedditJson","localize":[{"title":"åˆšçœ‹äº†ä¸€ç¯‡çº½çº¦æ—¶æŠ¥çš„æ–‡ç« ï¼Œè¯´è¯ç›‘ä¼šæ­£åœ¨å®¡æŸ¥è¿™ä¸ªå­ï¼Œæ˜¯æ€ä¹ˆå›äº‹....ğŸ®ğŸ®ğŸ®ğŸ®ï¼ˆè¯ç›‘ä¼šPLSé˜…è¯»ï¼‰ã€‚","the_new_excerpt":"è‡´æœ¬å­é‡Œçš„è¯ç›‘ä¼šå¼±æ™ºï¼šå»æ­»å§ã€‚ä½ ä¸ºä»€ä¹ˆä¸å¼€å§‹\nè°ƒæŸ¥ä¸ºä»€ä¹ˆå…¬å¸å¯ä»¥å…³é—­äº¤æ˜“ï¼Œä»¥ä¾¿ä»–ä»¬çš„å¯¹å†²åŸºé‡‘çš„æœ‹å‹ä»¬\nä¸è¦èµ”é’±ã€‚ä½†æ˜¯ï¼Œå½“äººä»¬è¾“é’±çš„æ—¶å€™ï¼Œå®Œå…¨å¯ä»¥ã€‚åƒä¸ªé¸¡å·´å§","locale":"zh"},{"title":"å‰›çœ‹äº†ä¸€ç¯‡ç´ç´„æ™‚å ±çš„æ–‡ç« ï¼Œèªªè­‰ç›£æœƒæ­£åœ¨å¯©æŸ¥é€™å€‹å­ï¼Œæ˜¯æ€éº¼å›äº‹....ğŸ®ğŸ®ğŸ®ğŸ®ï¼ˆè­‰ç›£æœƒPLSé–±è®€ï¼‰ã€‚","the_new_excerpt":"è‡´æœ¬å­è£çš„è­‰ç›£æœƒå¼±æ™ºï¼šå»æ­»å§ã€‚ä½ çˆ²ä»€éº¼ä¸é–‹å§‹\nèª¿æŸ¥çˆ²ä»€éº¼å…¬å¸å¯ä»¥é—œé–‰äº¤æ˜“ï¼Œä»¥ä¾¿ä»–å€‘çš„å°æ²–åŸºé‡‘çš„æœ‹å‹å€‘\nä¸è¦è³ éŒ¢ã€‚ä½†æ˜¯ï¼Œç•¶äººå€‘è¼¸éŒ¢çš„æ™‚å€™ï¼Œå®Œå…¨å¯ä»¥ã€‚å–«å€‹é›å·´å§","locale":"zh-Hant"}]}},"next":{"id":"RedditPost-l66f7o","excerpt":"","slug":"/reddit/r/wallstreetbets/comments/l66f7o/even_the_mooch_knows_were_coming_for_the_suits/","title":"Even the MOOCH knows weâ€™re coming for the suits!!!","__typename":"SocialMediaPost","date":"January 27, 2021","parent":{"__typename":"RedditJson","localize":[{"title":"è¿MOOCHéƒ½çŸ¥é“æˆ‘ä»¬æ˜¯å†²ç€è¥¿è£…æ¥çš„ï¼!","the_new_excerpt":null,"locale":"zh"},{"title":"é€£MOOCHéƒ½çŸ¥é“æˆ‘å€‘æ˜¯è¡ç€è¥¿è£ä¾†çš„ï¼!","the_new_excerpt":null,"locale":"zh-Hant"}]}}},"pageContext":{"id":"RedditPost-kv332t","previousId":"RedditPost-l6c5tg","nextId":"RedditPost-l66f7o","maxWidth":1024,"locale":"zh-Hant","hrefLang":"zh-Hant","originalPath":"/reddit/r/investing/comments/kv332t/eli_lilly_up_20_after_donanemab_shows_clinical/","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2506312863","2744905544","3493603132","3493603132","3513215887","386998304"]}